P/E ratio for Corcept Therapeutics (CORT)

P/E ratio history for Corcept Therapeutics from 2004 to 2026

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	30.4	-85.39%	🇺🇸 USA
Novartis NVS	22.3	-89.28%	🇨🇭 Switzerland
Pfizer PFE	18.3	-91.22%	🇺🇸 USA
Eli Lilly LLY	43.6	-79.09%	🇺🇸 USA
Merck MRK	36.0	-82.71%	🇺🇸 USA
Bristol-Myers Squibb BMY	16.3	-92.18%	🇺🇸 USA
MannKind Corp MNKD	212	1.89%	🇺🇸 USA
Esperion Therapeutics ESPR	-6.32	-103.03%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	42.7	-79.49%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.